Bullens Dominique M A, Decraene Ann, Seys Sven, Dupont Lieven J
Pediatrics Division, University Hospitals Leuven, 3000 Leuven, Belgium.
Clin Dev Immunol. 2013;2013:840315. doi: 10.1155/2013/840315. Epub 2013 Jan 17.
Since the discovery of IL-17 in 1995 as a T-cell cytokine, inducing IL-6 and IL-8 production by fibroblasts, and the report of a separate T-cell lineage producing IL-17(A), called Th17 cells, in 2005, the role of IL-17 has been studied in several inflammatory diseases. By inducing IL-8 production and subsequent neutrophil attraction towards the site of inflammation, IL-17A can link adaptive and innate immune responses. More specifically, its role in respiratory diseases has intensively been investigated. We here review its role in human respiratory diseases and try to unravel the question whether IL-17A only provides a link between the adaptive and innate respiratory immunity or whether this cytokine might also be locally produced by innate immune cells. We furthermore briefly discuss the possibility to reduce local IL-17A production as a treatment option for respiratory diseases.
自1995年白细胞介素-17(IL-17)作为一种T细胞细胞因子被发现,它可诱导成纤维细胞产生白细胞介素-6(IL-6)和白细胞介素-8(IL-8),以及2005年报道了一种单独的产生IL-17A的T细胞谱系(称为Th17细胞)以来,IL-17在多种炎症性疾病中的作用已得到研究。通过诱导IL-8产生以及随后嗜中性粒细胞向炎症部位的趋化,IL-17A可将适应性免疫反应和先天性免疫反应联系起来。更具体地说,其在呼吸道疾病中的作用已得到深入研究。我们在此综述其在人类呼吸道疾病中的作用,并试图阐明IL-17A是仅在适应性呼吸道免疫和先天性呼吸道免疫之间起连接作用,还是这种细胞因子也可能由先天性免疫细胞在局部产生这一问题。此外,我们还简要讨论了降低局部IL-17A产生作为呼吸道疾病治疗选择的可能性。